Electromed, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2022, compared with fiscal 2021. The source filing is an annual report, not a quarterly filing; the request metadata references 2021 Q4.
Business Context
Electromed develops, manufactures and sells SmartVest high-frequency chest wall oscillation airway-clearance systems for patients with compromised pulmonary function. Revenue is generated primarily through direct U.S. home-care sales supported by physician referrals and third-party reimbursement, with additional institutional, home-care distributor and international sales.
- U.S. revenue was $41.7 million; approximately 91% was home-care revenue and 4% was hospital revenue.
- The company had 156 employees and 52 field sales employees as of June 30, 2022.
- Management estimated the served U.S. HFCWO market at approximately $220 million to $240 million, with adoption growth of approximately 5%.
Financial Performance and Liquidity
| Metric | Fiscal 2022 | Fiscal 2021 | Change |
|---|---|---|---|
| Revenue | $41.659 million | $35.756 million | 16.5% increase |
| Gross profit | $31.442 million | $27.305 million | 15.2% increase |
| Gross margin | 75.5% | 76.4% | Down 0.9 percentage points |
| Operating income | $2.972 million | $3.140 million | 5.4% decrease |
| Net income | $2.305 million | $2.362 million | 2.4% decrease |
| Diluted EPS | $0.26 | $0.27 | Decrease |
| Operating cash flow | $(0.686) million | $3.077 million | Decline |
| Capital expenditures and other investing cash uses | $(1.525) million | $(0.448) million | Higher spending |
| Cash used in financing activities | $(1.525) million | $(1.219) million | Higher use |
| Cash and cash equivalents | $8.153 million | $11.889 million | Decrease |
SG&A increased 20.8% to $27.114 million, reflecting higher sales, reimbursement and marketing staffing, systems investments, travel, recruiting, insurance and shareholder activism costs. R&D declined 21.3% to $1.356 million, or 3.3% of revenue. The effective tax rate was 23.1%, compared with 25.4% in fiscal 2021.
Working capital was approximately $27.389 million at June 30, 2022. Accounts receivable increased to $21.052 million, largely because Medicare sales have a 13-month payment cycle, while inventory increased to $3.178 million. Total liabilities were $7.191 million and shareholders’ equity was $34.173 million.
The renewed revolving credit facility provides up to $2.5 million, subject to borrowing-base limitations. No principal was outstanding at June 30, 2022, and the full $2.5 million was available. The facility expires December 18, 2023, and includes a minimum tangible net worth covenant of $10.125 million and restrictions on additional debt and dividends.
Material Changes Versus the Prior Period
- Home-care revenue rose 15.2% to $38.004 million, driven by higher referrals and approvals, increased sales capacity, improved clinic access and patient flow, a Medicare allowable-rate increase effective January 1, 2022, and the CMS COVID-19 waiver.
- Home-care distributor revenue increased 161.8% to $1.474 million, primarily due to demand from a major distribution partner.
- Institutional revenue increased 7.2% to $1.660 million as hospitals resumed HFCWO utilization.
- International revenue decreased 20.8% to $0.521 million; international expansion is not a primary focus.
- Gross margin declined because of higher raw-material and shipping costs and increased patient-training expenses.
- Operating income and net income declined despite revenue growth because of increased SG&A, shareholder activism expenses and higher product costs.
- Operating cash flow turned negative, primarily because of increased accounts receivable, inventory purchases, prepaid expenses, tax payments and other working-capital needs.
- The company repurchased 120,416 shares during fiscal 2022 for $1.448 million, leaving approximately $427,000 available under the authorization at June 30, 2022.
Guidance, Outlook, Risks and Unusual Items
- Management expected to launch a next-generation SmartVest and complete the related FDA 510(k) clearance process in the first half of fiscal 2023.
- Fiscal 2023 priorities included adding five sales territories and representatives, increasing direct-to-consumer and physician marketing, expanding clinical evidence, improving customer support and broadening adoption among adult pulmonology and bronchiectasis patients.
- R&D spending was expected to decline to approximately 2.0% to 3.0% of revenue in fiscal 2023 as product development and testing concluded. Management also expects the next-generation product to have a lower cost of goods.
- Management believed cash, operating cash flow, working capital and available borrowings would be adequate for fiscal 2023, but future liquidity depends partly on collections and reimbursement timing.
- The CMS respiratory-device waiver remained in effect through an additional 90-day period beginning July 15, 2022. Expiration could reduce Medicare referrals, approvals and revenue.
- Key risks include COVID-19 developments, reimbursement reductions or denials, expiration of CMS waivers, supply shortages, inflation in materials and wages, shipping costs, regulatory clearance, competition, cybersecurity, data privacy, sales-force expansion and renewal of the credit facility.
- The company disclosed a putative class action related to a prior data breach involving customer protected health information and employee information. The parties were negotiating a settlement, but the ultimate outcome and potential loss were not determinable.
- A shareholder activism matter concluded with a cooperation agreement in September 2021; related professional and legal costs increased fiscal 2022 expenses.
- Former CFO Michael J. MacCourt ceased serving and was terminated effective July 1, 2022. Michelle C. Wirtz served as interim CFO as of the filing date.
- The financial statements received an unqualified audit opinion from RSM US LLP. The critical audit matter concerned measurement of customer revenue net of payer and collection adjustments.
Investor Verification Items
- Verify the sustainability of revenue growth after the CMS waiver expires and as Medicare reimbursement and documentation requirements normalize.
- Assess accounts-receivable aging, collection performance and the assumptions used for payer adjustments and variable consideration.
- Monitor gross-margin effects from component shortages, freight inflation, reimbursement mix and the expected cost structure of the next-generation device.
- Confirm the timing and success of FDA 510(k) clearance and commercialization of the next-generation SmartVest.
- Review operating cash flow conversion, inventory growth and capital spending requirements relative to the company’s $8.153 million cash balance.
- Review the data-breach litigation settlement, potential exposure and any related insurance recoveries or costs.
- Review compliance with credit-facility covenants and renewal risk before the December 18, 2023 expiration.